(Total Views: 661)
Posted On: 06/04/2020 11:10:40 AM
Post# of 154179
Keep in mind that others don't have such a big safety-database and thus need more patients to establish safety.
Further: what use are trials with hundreds of patients, if it takes ages for smaller companies to fill them (and CytoDyn is no exception to slow enrollment).
I'd feel more comfortable if the mild/moderate trial comprised 100-150 patients and the interim analysis for the severe trial 100, but given that the pandemic is starting to slow down and the difficulties for CYDY to quickly enroll, the smaller sizes might have been a blessing, provided leronlimab works as excellent as we all suspect.
Further: what use are trials with hundreds of patients, if it takes ages for smaller companies to fill them (and CytoDyn is no exception to slow enrollment).
I'd feel more comfortable if the mild/moderate trial comprised 100-150 patients and the interim analysis for the severe trial 100, but given that the pandemic is starting to slow down and the difficulties for CYDY to quickly enroll, the smaller sizes might have been a blessing, provided leronlimab works as excellent as we all suspect.
(1)
(0)
